SINTX Technologies (SINT) Q4 2025 earnings summary

Executive summary

• Focused on advanced ceramics, especially silicon nitride for biomedical and antipathogenic applications, with a strategic shift away from non-core OEM contracts to proprietary medical devices.

• Received FDA 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025, marking entry into reconstructive foot and ankle surgery.

• Implemented cost-saving measures, including workforce reduction and ceasing armor plant operations, to improve efficiency.

Financial highlights

• Product revenue for 2025 was $0.7M, down 41% year-over-year; grant and contract revenue was $0.3M, down 82%.

• Total revenue declined 65% to $1.0M; gross profit fell 78% to $0.5M.

• Net loss for 2025 was $10.4M, a 6% improvement from $11.0M in 2024.

• Operating expenses decreased 31% to $11.2M, reflecting lower R&D, sales, and marketing costs, and the absence of prior year armor exit and reduction in force expenses.

• Cash used in operations was $8.6M, unchanged from 2024; cash and equivalents at year-end were $4.1M.

• Accumulated deficit reached $292.1M as of December 31, 2025.

Outlook and guidance

• Revenue expected to grow in 2026, driven by new product launches, including the SiNAPTIC® wedge system and OsseoSculpt™ biologic.

• Strategic focus on commercializing proprietary silicon nitride-based medical devices for higher margins and sustainable growth.

• Substantial doubt remains about the ability to continue as a going concern without additional financing.